BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

Rhea-AI Summary

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced two poster presentations at the San Antonio Breast Cancer Symposium (SABCS), Dec 9-12, 2025, in San Antonio, Texas. Both posters feature BBO-10203, described as a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction.

Details: a Late-Breaking Pre-clinical poster (Abstract 3568, Presentation PS2-12-06) on Dec 10, 5:00–6:30 p.m. CT by Kerstin Sinkevicius, PhD, reports tumor growth inhibition alone and combined with fulvestrant or ribociclib without inducing hyperglycemia. A Trials-in-Progress poster (Abstract 203, Presentation PS5-07-06) on Dec 12, 12:30–2:00 p.m. CT by Andreas Varkaris, MD, PhD, outlines the phase 1a/1b BREAKER-101 study of BBO-10203 in advanced solid tumors.

News Market Reaction – BBOT

-0.50%

1 alert

-0.50% News Effect

On the day this news was published, BBOT declined 0.50%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced two poster presentations featuring BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, at the San Antonio Breast Cancer Symposium (SABCS) being held December 9-12, 2025, in San Antonio, Texas. The abstracts released today can be found on the SABCS website here.

Late Breaking Pre-clinical Poster Details:

• Title: BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fulvestrant or ribociclib in breast cancer models without inducing hyperglycemia
• Presentation Number: PS2-12-06
• Abstract Number: 3568
• Session Date/Time: Wednesday, December 10, from 5:00 p.m. - 6:30 p.m. CT
• Presenter: Kerstin Sinkevicius, PhD, Vice President, Pharmacology, BBOT
  

Trials in Progress Poster Details:

• Title: BREAKER-101: a phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors
• Presentation Number: PS5-07-06
• Abstract Number: 203
• Session Date/Time: Friday, December 12, from 12:30 p.m. – 2:00 p.m. CT
• Presenter: Andreas Varkaris, MD, PhD, Attending Physician and Investigator, Massachusetts General Hospital
  

About BBO-10203
BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Kα, resulting in the inhibition of RAS-driven PI3Kα-AKT signaling in tumors without the risk of hyperglycemia. This novel mechanism of action makes BBO-10203 agnostic to the mutational status of either RAS or PI3Kα providing the potential to treat tumors driven by KRAS or PI3Kα mutations, the two most mutated oncogenes in human cancer. BBO-10203 is being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR+/HER2- breast cancer, and KRAS mutant colorectal or non-small cell lung cancer.

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

BBOT Contacts:

Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com

FAQ

When will BBOT present BBO-10203 posters at SABCS 2025?

BBOT will present on Dec 10, 2025 (5:00–6:30 p.m. CT) and Dec 12, 2025 (12:30–2:00 p.m. CT).

What is the focus of the BBOT late‑breaking pre‑clinical poster at SABCS (BBOT, Dec 10, 2025)?

The late‑breaking pre‑clinical poster (Abstract 3568) describes BBO-10203 inhibiting tumor growth alone and with fulvestrant or ribociclib without inducing hyperglycemia.

What does the BREAKER-101 trial poster (BBOT, Dec 12, 2025) describe?

The Trials‑in‑Progress poster (Abstract 203) outlines the phase 1a/1b open‑label BREAKER-101 study evaluating safety, tolerability, PK, and efficacy of BBO-10203 in advanced solid tumors.

Who are the BBOT presenters for the SABCS 2025 posters?

Presenters are Kerstin Sinkevicius, PhD (Dec 10 pre‑clinical poster) and Andreas Varkaris, MD, PhD (Dec 12 trials‑in‑progress poster).

Where can I find the BBOT SABCS 2025 abstracts and poster numbers?

Abstracts are listed on the SABCS website: pre‑clinical poster Abstract 3568, PS2-12-06; trials poster Abstract 203, PS5-07-06.